Page 4 - Landmark Study News Today

DGAP-News: Moderna, Inc. / Key word(s): Miscellaneous Moderna, Inc.: Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day 08.09.2022 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Moderna Reviews Clinical Trial Programs Across Port...

Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefitInterim data from

/CNW/ - More than a million Canadians are forecast to be living with dementia by 2030, a date by which it is estimated that approximately 21 people will be...

/CNW/ - September 6, 2022 – Canada faces serious challenges in supporting people living with dementia and their care partners over the next three decades....

The blood pressure–lowering effects of dietary salt substitutes have a clear protective effect on hard clinical outcomes, leading to a reduction in heart attack, stroke, and death, a meta-analysis shows.

Safe and accessible reproductive health care is a basic right that is supported by science, medicine, and respect for human dignity.

Intense with other very variance in the study confirms that, right? >> this was a landmark study looked at 52000 people with omicron in 16 or 17000 delta. but they found was that among the 52000 people with omicron severe illness was rare. nobody ended up on a ventilator and its really telling us it is intrinsically more mild in addition to the population immunity of which the natural immunity type was sixfold times more protective than in the general population and vaccinate immunity. it is tel...

Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple SclerosisMonday, March 14th @ 11 am ET, registration details below - read this article along with other careers information, tips and advice on BioSpace

Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that it will host a virtual Key Opinion Leader (KOL) webinar event, “Foralumab Clinical Update in Multiple Sclerosis: A Landmark ...

Monday, March 14th @ 11 am ET, registration details belowNEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling